Management of Acute Gout Flares and Follow-up Care

Acute Gout Flare Management

The American College of Rheumatology recommends corticosteroids, NSAIDs, or colchicine as first-line therapy for acute gout flares, with treatment initiated as early as possible for optimal outcomes 1, 2
Corticosteroids are recommended as first-line therapy in patients without contraindications due to their safety profile and low cost, with oral prednisone 30-35 mg/day for 3-5 days or 0.5 mg/kg/day for 5-10 days 1, 2
NSAIDs at full anti-inflammatory doses are effective when started promptly, but should be avoided in patients with renal disease, heart failure, or cirrhosis 1, 6
Colchicine is most effective when started within 12 hours of symptom onset, with a low-dose regimen of 1.2 mg followed by 0.6 mg one hour later 6, 7
The European League Against Rheumatism recommends intra-articular corticosteroid injection for single joint involvement 5

The American College of Rheumatology recommends against initiating long-term urate-lowering therapy (ULT) after a first gout attack or in patients with infrequent attacks (<2 per year), but indicates ULT is indicated for patients with recurrent gout flares, tophi, urate arthropathy, or renal stones 1, 2, 5
When initiating ULT, the American College of Rheumatology recommends starting with low-dose allopurinol (100 mg/day) and gradually increasing the dose every 2-4 weeks to achieve a target serum urate level <6 mg/dL 3, 4
Prophylaxis with low-dose colchicine (0.5-1 mg/day) or low-dose NSAIDs is essential when starting ULT to prevent acute flares, and should be continued for at least 6 months 2, 5, 7
Lifestyle modifications, including weight loss for overweight/obese patients, limiting alcohol intake, and limiting intake of high-fructose corn syrup and sugar-sweetened beverages, are recommended to reduce the risk of gout flares 2, 4, 5

In patients with renal impairment, corticosteroids are generally safer than NSAIDs or colchicine, and allopurinol dosing should be adjusted based on creatinine clearance 1, 3
In patients with hepatic impairment, colchicine dose reduction should be considered, and patients should be monitored closely for adverse effects 4, 7
Regular monitoring of estimated glomerular filtration rate (eGFR) and screening for associated comorbidities (coronary heart disease, heart failure, stroke, diabetes) are recommended 1, 5, 6